Payment overview · 2025
General Payments
$233.16
11 reported records · 5 companies
Healthcare provider profile · identity verified
Michael Alocci, MD
Allopathic & Osteopathic Physicians|Internal Medicine · DUNMORE, PA · NPI 1487634531
Verified facts
What the public records show
CMS Open Payments records show Michael Alocci, MD received $233.16 in general payments during 2025 across 11 reported records.
ABBVIE INC. accounted for 61.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 8 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 38 claims for Synthroid by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 239 claims for Eliquis by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $142.16 | 61.0% | 7 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $28.42 | 12.2% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $24.73 | 10.6% | 1 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $19.93 | 8.6% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $17.92 | 7.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $233.16 | 11 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $61.22 | 2 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $41.39 | 2 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $39.55 | 3 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $28.42 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $24.73 | 1 | 2025 |
Source payment records
|
|||||
| CAMZYOS Normalized: camzyos |
Drug | E.R. Squibb & Sons, L.L.C. | $19.93 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $17.92 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $17.92 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 18 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
38 | suppressed by CMS |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
239 | 41 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 604 | 130 |
| Amlodipine Besylate | Amlodipine Besylate | 553 | 117 |
| Levothyroxine Sodium | Levothyroxine Sodium | 488 | 94 |
| Omeprazole | Omeprazole | 483 | 100 |
| Lisinopril | Lisinopril | 475 | 124 |
| Metoprolol Succinate | Metoprolol Succinate | 396 | 90 |
| Alprazolam | Alprazolam | 349 | 55 |
| Lorazepam | Lorazepam | 338 | 52 |
| Losartan Potassium | Losartan Potassium | 333 | 74 |
| Metformin Hcl | Metformin Hcl | 318 | 71 |
| Furosemide | Furosemide | 276 | 64 |
| Gabapentin | Gabapentin | 264 | 38 |
| Azithromycin | Azithromycin | 255 | 177 |
| Pantoprazole Sodium | Pantoprazole Sodium | 249 | 55 |
| Hydrochlorothiazide | Hydrochlorothiazide | 247 | 56 |
| Eliquis | Apixaban | 239 | 41 |
| Simvastatin | Simvastatin | 229 | 47 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 211 | 22 |
| Metoprolol Tartrate | Metoprolol Tartrate | 198 | 46 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 196 | 44 |
| Allopurinol | Allopurinol | 195 | 40 |
| Potassium Chloride | Potassium Chloride | 170 | 37 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 158 | 18 |
| Glimepiride | Glimepiride | 150 | 38 |
| Tramadol Hcl | Tramadol Hcl | 145 | 30 |
| Tamsulosin Hcl | Tamsulosin Hcl | 143 | 35 |
| Oxycodone Hcl | Oxycodone Hcl | 137 | 12 |
| Atenolol | Atenolol | 135 | 36 |
| Escitalopram Oxalate | Escitalopram Oxalate | 127 | 29 |
| Clonazepam | Clonazepam | 125 | 17 |
| Irbesartan | Irbesartan | 114 | 21 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 106 | 40 |
| Sertraline Hcl | Sertraline Hcl | 105 | 21 |
| Methylprednisolone | Methylprednisolone | 98 | 74 |
| Fluticasone Propionate | Fluticasone Propionate | 91 | 27 |
| Pravastatin Sodium | Pravastatin Sodium | 91 | 25 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 90 | 72 |
| Meloxicam | Meloxicam | 90 | 22 |
| Buspirone Hcl | Buspirone Hcl | 87 | 21 |
| Citalopram Hbr | Citalopram Hydrobromide | 87 | 14 |
| Ezetimibe | Ezetimibe | 87 | 24 |
| Clopidogrel | Clopidogrel Bisulfate | 86 | 17 |
| Fluoxetine Hcl | Fluoxetine Hcl | 83 | 17 |
| Zolpidem Tartrate | Zolpidem Tartrate | 81 | 17 |
| Carvedilol | Carvedilol | 79 | 14 |
| Benazepril Hcl | Benazepril Hcl | 75 | 15 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 74 | 18 |
| Warfarin Sodium | Warfarin Sodium | 72 | 14 |
| Torsemide | Torsemide | 68 | 16 |
| Labetalol Hcl | Labetalol Hcl | 67 | 12 |
| Trazodone Hcl | Trazodone Hcl | 65 | 11 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 63 | 47 |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 61 | suppressed |
| Finasteride | Finasteride | 61 | 14 |
| Ibuprofen | Ibuprofen | 59 | 15 |
| Famotidine | Famotidine | 55 | 17 |
| Spironolactone | Spironolactone | 55 | 12 |
| Metformin Hcl Er | Metformin Hcl | 54 | 11 |
| Doxycycline Hyclate | Doxycycline Hyclate | 53 | 32 |
| Clonidine Hcl | Clonidine Hcl | 52 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 50 | 11 |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 49 | 16 |
| Pregabalin | Pregabalin | 49 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 49 | suppressed |
| Diazepam | Diazepam | 46 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 44 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 43 | 11 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 42 | 13 |
| Myrbetriq | Mirabegron | 42 | suppressed |
| Prednisone | Prednisone | 41 | 11 |
| Paroxetine Hcl | Paroxetine Hcl | 39 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 38 | suppressed |
| Synthroid | Levothyroxine Sodium | 38 | suppressed |
| Valsartan | Valsartan | 38 | 11 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 37 | 13 |
| Alendronate Sodium | Alendronate Sodium | 36 | suppressed |
| Lovastatin | Lovastatin | 36 | suppressed |
| Temazepam | Temazepam | 36 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 35 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 35 | suppressed |
| Sucralfate | Sucralfate | 35 | suppressed |
| Celecoxib | Celecoxib | 34 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 34 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 33 | 19 |
| Memantine Hcl | Memantine Hcl | 33 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 32 | suppressed |
| Jardiance | Empagliflozin | 32 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 32 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 31 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 30 | suppressed |
| Amoxicillin | Amoxicillin | 29 | 26 |
| Cefuroxime | Cefuroxime Axetil | 28 | 23 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 26 | 20 |
| Glipizide Er | Glipizide | 26 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 26 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 25 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 25 | 19 |
| Felodipine Er | Felodipine | 25 | suppressed |
| Fentanyl | Fentanyl | 25 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 25 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 25 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 25 | suppressed |
| Baclofen | Baclofen | 24 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 24 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 24 | 17 |
| Fluconazole | Fluconazole | 23 | 13 |
| Levetiracetam | Levetiracetam | 23 | suppressed |
| Levofloxacin | Levofloxacin | 23 | 14 |
| Morphine Sulfate Er | Morphine Sulfate | 23 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 23 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 22 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 22 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 22 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 22 | suppressed |
| Nifedipine Er | Nifedipine | 21 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 21 | 21 |
| Clobetasol Propionate | Clobetasol Propionate | 19 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 19 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 19 | suppressed |
| Mounjaro | Tirzepatide | 19 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 19 | 17 |
| Nitroglycerin | Nitroglycerin | 19 | 11 |
| Xarelto | Rivaroxaban | 19 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 18 | suppressed |
| Glipizide | Glipizide | 18 | suppressed |
| Ozempic | Semaglutide | 18 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 18 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 17 | suppressed |
| Cholestyramine Light | Cholestyramine | 17 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 17 | suppressed |
| Phenelzine Sulfate | Phenelzine Sulfate | 17 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 17 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 17 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 16 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 16 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 16 | suppressed |
| Hydrocortisone | Hydrocortisone | 16 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 16 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 15 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Cephalexin | Cephalexin | 14 | 13 |
| Digoxin | Digoxin | 14 | suppressed |
| Ondansetron Odt | Ondansetron | 14 | suppressed |
| Ramipril | Ramipril | 14 | suppressed |
| Tradjenta | Linagliptin | 14 | suppressed |
| Aripiprazole | Aripiprazole | 13 | suppressed |
| Carbidopa-Levodopa-Entacapone | Carbidopa/Levodopa/Entacapone | 13 | suppressed |
| Creon | Lipase/Protease/Amylase | 13 | suppressed |
| Econazole Nitrate | Econazole Nitrate | 13 | suppressed |
| Januvia | Sitagliptin Phosphate | 13 | suppressed |
| Naproxen | Naproxen | 13 | suppressed |
| Nateglinide | Nateglinide | 13 | suppressed |
| Oxycontin | Oxycodone Hcl | 13 | suppressed |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 13 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 13 | suppressed |
| Verapamil Er | Verapamil Hcl | 13 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 13 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 12 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 12 | suppressed |
| Carisoprodol | Carisoprodol | 12 | suppressed |
| Crestor | Rosuvastatin Calcium | 12 | suppressed |
| Dantrolene Sodium | Dantrolene Sodium | 12 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 12 | suppressed |
| Ibu | Ibuprofen | 12 | suppressed |
| Niacin Er | Niacin | 12 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 12 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 12 | suppressed |
| Trulicity | Dulaglutide | 12 | suppressed |
| Zonisamide | Zonisamide | 12 | suppressed |
| Brilinta | Ticagrelor | 11 | suppressed |
| Bumetanide | Bumetanide | 11 | suppressed |
| Cartia Xt | Diltiazem Hcl | 11 | suppressed |
| Colchicine | Colchicine | 11 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 11 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 11 | suppressed |
| Prasugrel Hcl | Prasugrel Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $233.16 · 11 records | ABBVIE INC. | CAMZYOS, Dexcom G6 Transmitter, FREESTYLE LIBRE 3, Ozempic, QULIPTA, Rybelsus, UBRELVY, VRAYLAR | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error